|
1
|
Fardet L, Dupuy A, Gain M, Kettaneh A,
Chérin P, Bachelez H, Dubertret L, Lebbe C, Morel P and Rybojad M:
Factors associated with underlying malignancy in a retrospective
cohort of 121 patients with dermatomyositis. Medicine (Baltimore).
88:91–97. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stertz G: Polymyositis. Berl Klin
Wochenschr. 53:4891916.
|
|
3
|
So MW, Koo BS, Kim YG, Lee CK and Yoo B:
Idiopathic inflammatory myopathy associated with malignancy: A
retrospective cohort of 151 Korean patients with dermatomyositis
and polymyositis. J Rheumatol. 38:2432–2435. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lu X, Yang H, Shu X, Chen F, Zhang Y,
Zhang S, Peng Q, Tian X and Wang G: Factors predicting malignancy
in patients with polymyositis and dermatomyostis: A systematic
review and meta-analysis. PLoS One. 9:e941282014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fang YF, Wu YJ, Kuo CF, Luo SF and Yu KH:
Malignancy in dermatomyositis and polymyositis: analysis of 192
patients. Clin Rheumatol. 35:1977–1984. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zampieri S, Valente M, Adami N, Biral D,
Ghirardello A, Rampudda ME, Vecchiato M, Sarzo G, Corbianco S, Kern
H, et al: Polymyositis, dermatomyositis and malignancy: A further
intriguing link. Autoimmun Rev. 9:449–453. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zantos D, Zhang Y and Felson D: The
overall and temporal association of cancer with polymyositis and
dermatomyositis. J Rheumatol. 21:1855–1859. 1994.PubMed/NCBI
|
|
8
|
Buchbinder R and Hill CL: Malignancy in
patients with inflammatory myopathy. Curr Rheumatol Rep. 4:415–426.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Madan V, Chinoy H, Griffiths CE and Cooper
RG: Defining cancer risk in dermatomyositis. Part I. Clin Exp
Dermatol. 34:451–455. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zahr ZA and Baer AN: Malignancy in
myositis. Curr Rheumatol Rep. 13:208–215. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jouary T, Gracia C, Lalanne N, Vital A,
Taieb A and Delaunay M: Rapidly lethal dermatomyositis associated
with metastatic melanoma. J Eur Acad Dermatol Venereol. 22:399–401.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Teoh JW, Yunus RM, Hassan F, Ghazali N and
Abidin ZA: Nasopharyngeal carcinoma in dermatomyositis patients: A
10-year retrospective review in Hospital Selayang, Malaysia. Rep
Pract Oncol Radiother. 19:332–336. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Noda T, Iijima M, Noda S, Maeshima S,
Nakanishi H, Kimura S, Koike H, Ishigaki S, Iguchi Y, Katsuno M and
Sobue G: Gene expression profile of inflammatory myopathy with
malignancy is similar to that of dermatomyositis rather than
polymyositis. Intern Med. 55:2571–2580. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hoshino K, Muro Y, Sugiura K, Tomita Y,
Nakashima R and Mimori T: Anti-MDA5 and anti-TIF1-gamma antibodies
have clinical significance for patients with dermatomyositis.
Rheumatology (Oxford). 49:1726–1733. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bohan A and Peter JB: Polymyositis and
dermatomyositis (second of two parts). N Engl J Med. 292:403–407.
1975. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ikeda S, Arita M, Misaki K, Mishima S,
Takaiwa T, Nishiyama A, Ito A, Furuta K, Yokoyama T, Tokioka F, et
al: Incidence and impact of interstitial lung disease and
malignancy in patients with polymyositis, dermatomyositis, and
clinically amyopathic dermatomyositis: A retrospective cohort
study. SpringerPlus. 4:2402015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Stockton D, Doherty VR and Brewster DH:
Risk of cancer in patients with dermatomyositis or polymyositis,
and follow-up implications: A Scottish population-based cohort
study. Br J Cancer. 85:41–45. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Leatham H, Schadt C, Chisolm S, Fretwell
D, Chung L, Callen JP and Fiorentino D: Evidence supports blind
screening for internal malignancy in dermatomyositis: Data from 2
large US dermatology cohorts. Medicine (Baltimore). 97:e96392018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
de Souza FH and Shinjo SK: Newly diagnosed
dermatomyositis in the elderly as predictor of malignancy. Rev Bras
Reumatol. 52:713–721. 2012.PubMed/NCBI
|
|
20
|
Sigurgeirsson B, Lindelof B, Edhag O and
Allander E: Risk of cancer in patients with dermatomyositis or
polymyositis. A population-based study. N Engl J Med. 326:363–367.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ungprasert P, Leeaphorn N, Hosiriluck N,
Chaiwatcharayut W, Ammannagari N and Raddatz DA: Clinical features
of inflammatory myopathies and their association with malignancy: A
systematic review in Asian population. ISRN Rheumatology.
2013:5093542013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen D, Yuan S, Wu X, Li H, Qiu Q, Zhan Z,
Ye Y, Lian F, Liang L, Xu H and Yang X: Incidence and predictive
factors for malignancies with dermatomyositis: A cohort from
southern China Clin Exp Rheumatol. 32:615–621. 2014.
|
|
23
|
Zhang W, Jiang SP and Huang L:
Dermatomyositis and malignancy: A retrospective study of 115 cases.
Eur Rev Med Pharmacol Sci. 13:77–80. 2009.PubMed/NCBI
|
|
24
|
Wei KR, Zheng RS, Zhang SW, Liang ZH, Ou
ZX and Chen WQ: Nasopharyngeal carcinoma incidence and mortality in
China in 2010. Chin J Cancer. 33:381–387. 2014.PubMed/NCBI
|
|
25
|
Hill CL, Zhang Y, Sigurgeirsson B, Pukkala
E, Mellemkjaer L, Airio A, Evans SR and Felson DT: Frequency of
specific cancer types in dermatomyositis and polymyositis: A
population-based study. Lancet. 357:96–100. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mebazaa A, Boussen H, Nouira R, Rokbani L,
Ben Osman-Dhahri A, Bouaouina N, Laouani-Kechrid C, Louzir B, Zahaf
A and Kamoun MR: Dermatomyositis and malignancy in Tunisia: A
multicenter national retrospective study of 20 cases. J Am Acad
Dermatol. 48:530–534. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Travassos AR, Borges-Costa J, Filipe P and
Marques MS: Malignancy associated with dermatomyositis-A
retrospective single-center study with 33 patients. Acta Reumatol
Port. 38:92–97. 2013.PubMed/NCBI
|
|
28
|
Azuma K, Yamada H, Ohkubo M, Yamasaki Y,
Yamasaki M, Mizushima M and Ozaki S: Incidence and predictive
factors for malignancies in 136 Japanese patients with
dermatomyositis, polymyositis and clinically amyopathic
dermatomyositis. Mod Rheumatol. 21:178–183. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fung WK, Chan HL and Lam WM: Amyopathic
dermatomyositis in Hong Kong-Association with nasopharyngeal
carcinoma. Int J Dermatol. 37:659–663. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yosipovitch G, Tan A, LoSicco K, Manabat
CG, Kannagra A, Carroll C, Chan YH, Ng P and Jorizzo J: A
comparative study of clinical characteristics, work-up, treatment,
and association to malignancy in dermatomyositis between two
tertiary skin centers in the USA and Singapore. Int J Dermatol.
52:813–819. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Andras C, Ponyi A, Constantin T, Csiki Z,
Szekanecz E, Szodoray P and Dankó K: Dermatomyositis and
polymyositis associated with malignancy: A 21-year retrospective
study. J Rheumatol. 35:438–444. 2008.PubMed/NCBI
|
|
32
|
Wakata N, Kurihara T, Saito E and
Kinoshita M: Polymyositis and dermatomyositis associated with
malignancy: A 30-year retrospective study. Int J Dermatol.
41:729–734. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Qiang JK, Kim WB, Baibergenova A and
Alhusayen R: Risk of malignancy in dermatomyositis and
polymyositis: A systematic review and meta-analysis. J Cutan Med
Surg. 21:131–136. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Masuda H, Urushibara M and Kihara K:
Successful treatment of dermatomyositis associated with
adenocarcinoma of the prostate after radical prostatectomy. J Urol.
169:10842003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yoshinaga A, Hayashi T, Ishii N, Ohno R,
Watanabe T and Yamada T: Successful cure of dermatomyositis after
treatment of nonseminomatous testicular cancer. Int J Urol.
12:593–595. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mahe E, Descamps V, Burnouf M and Crickx
B: A helpful clinical sign predictive of cancer in adult
dermatomyositis: Cutaneous necrosis. Arch Dermatol.
139:5392003.PubMed/NCBI
|
|
37
|
Giovannucci E, Harlan DM, Archer MC,
Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M,
Regensteiner JG and Yee D: Diabetes and cancer: A consensus report.
Diabetes Care. 33:1674–1685. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Vigneri P, Frasca F, Sciacca L, Pandini G
and Vigneri R: Diabetes and cancer. Endocr Relat Cancer.
16:1103–1123. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lukanova A, Zeleniuch-Jacquotte A, Lundin
E, Micheli A, Arslan AA, Rinaldi S, Muti P, Lenner P, Koenig KL,
Biessy C, et al: Prediagnostic levels of C-peptide, IGF-I, IGFBP
−1, −2 and −3 and risk of endometrial cancer. Int J Cancer.
108:262–268. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yang J, Nishihara R, Zhang X, Ogino S and
Qian ZR: Energy sensing pathways: Bridging type 2 diabetes and
colorectal cancer? J Diabetes Complications. 31:1228–1236. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Betteridge ZE, Gunawardena H and McHugh
NJ: Novel autoantibodies and clinical phenotypes in adult and
juvenile myositis. Arthritis Res Ther. 13:2092011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Casciola-Rosen L and Mammen AL: Myositis
autoantibodies. Curr Opin Rheumatol. 24:602–608. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Targoff IN, Mamyrova G, Trieu EP, Perurena
O, Koneru B, O'Hanlon TP, Miller FW and Rider LG; and Childhood
Myositis Heterogeneity Study Group, : International Myositis
Collaborative Study Group: A novel autoantibody to a 155-kd protein
is associated with dermatomyositis. Arthritis Rheum. 54:3682–3689.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kaji K, Fujimoto M, Hasegawa M, Kondo M,
Saito Y, Komura K, Matsushita T, Orito H, Hamaguchi Y, Yanaba K, et
al: Identification of a novel autoantibody reactive with 155 and
140 kDa nuclear proteins in patients with dermatomyositis: An
association with malignancy. Rheumatology (Oxford). 46:25–28. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chinoy H, Fertig N, Oddis CV, Ollier WE
and Cooper RG: The diagnostic utility of myositis autoantibody
testing for predicting the risk of cancer-associated myositis. Ann
Rheum Dis. 66:1345–1349. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gunawardena H, Wedderburn LR, North J,
Betteridge Z, Dunphy J, Chinoy H, Davidson JE, Cooper RG and McHugh
NJ; and Juvenile Dermatomyositis Research Group UK, : Clinical
associations of autoantibodies to a p155/140 kDa doublet protein in
juvenile dermatomyositis. Rheumatology (Oxford). 47:324–328. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ceribelli A, Isailovic N, De Santis M,
Generali E, Fredi M, Cavazzana I, Franceschini F, Cantarini L,
Satoh M and Selmi C: Myositis-specific autoantibodies and their
association with malignancy in Italian patients with polymyositis
and dermatomyositis. Clin Rheumatol. 36:469–475. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Trallero-Araguas E, Rodrigo-Pendas JA,
Selva-O'Callaghan A, Martínez-Gómez X, Bosch X, Labrador-Horrillo
M, Grau-Junyent JM and Vilardell-Tarrés M: Usefulness of anti-p155
autoantibody for diagnosing cancer-associated dermatomyositis: A
systematic review and meta-analysis. Arthritis Rheum. 64:523–532.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Dupont S, Zacchigna L, Cordenonsi M,
Soligo S, Adorno M, Rugge M and Piccolo S: Germ-layer specification
and control of cell growth by Ectodermin, a Smad4 ubiquitin ligase.
Cell. 121:87–99. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Sato S, Hirakata M, Kuwana M, Suwa A,
Inada S, Mimori T, Nishikawa T, Oddis CV and Ikeda Y:
Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese
patients with clinically amyopathic dermatomyositis. Arthritis
Rheum. 52:1571–1576. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ichimura Y, Matsushita T, Hamaguchi Y,
Kaji K, Hasegawa M, Tanino Y, Inokoshi Y, Kawai K, Kanekura T,
Habuchi M, et al: Anti-NXP2 autoantibodies in adult patients with
idiopathic inflammatory myopathies: Possible association with
malignancy. Ann Rheum Dis. 71:710–713. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Fiorentino DF, Chung LS, Christopher-Stine
L, Zaba L, Li S, Mammen AL, Rosen A and Casciola-Rosen L: Most
patients with cancer-associated dermatomyositis have antibodies to
nuclear matrix protein NXP-2 or transcription intermediary factor
1gamma. Arthritis Rheum. 65:2954–2962. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Albayda J, Pinal-Fernandez I, Huang W,
Parks C, Paik J, Casciola-Rosen L, Danoff SK, Johnson C,
Christopher-Stine L and Mammen AL: Antinuclear matrix protein 2
autoantibodies and edema, muscle disease, and malignancy risk in
dermatomyositis patients. Arthritis Care Res. (Hoboken).
69:1771–1776. 2017.
|
|
54
|
Airio A, Kautiainen H and Hakala M:
Prognosis and mortality of polymyositis and dermatomyositis
patients. Clin Rheumatol. 25:234–239. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Danko K, Ponyi A, Constantin T, Borgulya G
and Szegedi G: Long-term survival of patients with idiopathic
inflammatory myopathies according to clinical features: A
longitudinal study of 162 cases. Medicine (Baltimore). 83:35–42.
2004. View Article : Google Scholar : PubMed/NCBI
|
